| Status: Superseded | ||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED MARCH 2017. Refer to TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
||
|
||
Medicine details |
||
| Medicine name | panitumumab (Vectibix®) | |
| Formulation | 20 mg/ml solution for infusion | |
| Reference number | 2744 | |
| Indication | First-line treatment in combination with FOLFOX or FOLFIRI for adult patients with wild-type RAS metastatic colorectal cancer |
|
| Company | Amgen Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Submission type | Non-submission | |
| Status | Superseded | |
| Ratification by Welsh Government | 15/07/2015 | |
| Date of issue | 16/07/2015 | |
| NICE guidance | TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer |
|